TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adherence rate to postoperative weightbearing instructions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence rate to DVT prophylaxis instructions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of predicted dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV linkage and retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antiretroviral therapy adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measured immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fall Efficacy Scale -International
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Temporal- spatial characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the degree of ascription to dysfunctional beliefs
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of MV-associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of change of treatment plan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Nonalcoholic Fatty Liver Disease Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nonalcoholic Fatty Liver Disease Degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma phosphorylated Tau (p-tau181) biomarker level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in number of patients achieving low disease activity (cDAPSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in number of patients achieving Minimal Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in number of patients achieving a Body Surface Area (BSA) score of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial remission or complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ASCVD prediction risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gut microbiota diversity and composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum effective dose of protamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PML-RARA transcript levels of ≥6.5% at the end of induction therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Devices Deemed Functional
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary cortisol measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Toxin Neutralization Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment outcome with anti-seizure medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Second seizure/epilepsy diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: REG3α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Impaired lung diffusion capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Impaired spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physical activity based on the amount of moderate intensity walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step activity based on daily step counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait quality based on variability of stride time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline B-mode ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline 4 meter Gait Speed Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rate of Vanderbilt ADHD Diagnostic Parent Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting stress of parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of patients who decide to enroll in a Multiple Sclerosis Clinical Trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who remain in Multiple Sclerosis clinical trial until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Favorable Treatment Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners Parent Rating Scale-Revised Short
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: d2 Test of Attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants with Clinically significant changes in laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Clinically Significant Change in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in plasma concentration of soluble P-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUClast) of Prazosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Prazosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceleration time to ejection time (At/Et) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve of combined EPA and DHA plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCLisp (0-30 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rate from Type 3 transformation zone to Types 1 or 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: WHO BREF Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dysexecutive Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in overnight memory retention on the A-B verbal paired associates task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Aβ42/ Aβ40 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma P-tau181
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of belumosudil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain-derived blood biomarkers from baseline to post choking involved sex time point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in axonal microstructure from baseline to post choking involved sex time point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cerebral blood flow from baseline to post choking involved sex time point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of delirium after open heart surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity induced by primary yellow fever vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: WOMAC total score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: cartilage damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mothers' readiness levels for hygienic care of newborns
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health Belief Model
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Differential Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coping Strategy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability and Relevance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evaluation of ethanol levels in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dizziness visual analog scale (VAS) assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Choice Reaction Time (CRT) evaluation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of diagnosis of Central Precocious Puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean change in SF-36 physical component score (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean hemoglobin (Hb) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Household Food Waste
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relative abundance of gut microbiomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Restoration Success rate
Endpoint domain: Mortality/survival
Primary endpoint: Retinal Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression in the development of secondary sexual characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Progression in the speed of growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants with AIM Score > 4
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Domiciliary NIV adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Simultaneous Recumbent Cycling and Cognitive Training
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Simultaneous Recumbent Cycling and Cognitive Training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Induction to Onset of labor Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ocular graft-versus-host disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gait biomechanical data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical characteristics of knee cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteome analysis of tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in slow colonic transit (SCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to adjudicated ischemic stroke/transient ischemic attack (TIA)/systemic arterial embolism
Endpoint domain: Mortality/survival
Primary endpoint: HBV DNA copy number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory marker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in total room contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scores of the questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical effectiveness of HDRBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacodynamics and pharmacokinetics of Propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soft tissue volume change 0-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soft tissue volume change 0-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soft tissue volume change 3-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to obtain a molecular diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to make a treatment arm assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcriptome analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose time above 180mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lived experience of adolescents with XLH
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Supportive care needs and burden on carers
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: number of maternal deaths
Endpoint domain: Mortality/survival
Primary endpoint: number of venous thromboembolisms
Endpoint domain: Adverse events/effects
Primary endpoint: number of hemorrhages
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation of Empagliflozin
Endpoint domain: Adverse events/effects
Primary endpoint: GMT of neutralizing antibodies against Delta variant on D28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of neutralizing antibodies against Delta variant on D208
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in maximal oxygen uptake (VO2peak, ml/kg/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible individuals who consent to enroll in the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants assigned to iMD intervention with a response to referral question
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of iMD participants who complete 2 or more sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median scores on the perceived helpfulness of the iMD program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: average resting pressure of anal sphincter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient satisfaction survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stroke etiology awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroke Patient Education Retention (SPER) survey
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: EuroQOL-VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: success rate of IMA fluorescence imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Von Willebrand factor high molecular weight multimers (HMWM) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total opioid requirement postoperative day (POD) 1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG changes during TAVR procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High school graduation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: School retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Marriage
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Engagement in non-farm income generating activities
Endpoint domain: Life impact
Endpoint subdomain: Economic functioning
Primary endpoint: Digital financial literacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Socio-emotional skills index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BRIEF2 working memory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS-II T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Safe sleep behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: postoperative visual analog scales at rest and during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for rescue analgesics
Endpoint domain: Adverse events/effects
Primary endpoint: maximal minute ventilation (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haematological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Targeted grade ≥3 treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Grade ≥3 injection-site reactions (ISRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Type, severity, and frequency of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Foot Health Status Questionnaire (FHSQ) - Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of acute renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perceived clinical symptoms due to tobacco use and/or AP exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived psychological impact due to tobacco use and/or AP exposure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Burden due to tobacco use and/or AP exposure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Regional cerebral oxygen saturation %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: oxidative stress levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antioxidant markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Pain Rating Scales (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total number of Vocal fold movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Acoustic voice recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microelectrode recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the Hip-Knee-Ankle Angle (HKA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of study participants who receive HPV vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of blood pressure over time points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of biomarkers over time points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of heart rate over time points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of body weight over time points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity of DPP Typhoid assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-reported symptoms of allergies and infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parent-reported use of medications and/or a medical device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Parent-reported hospitalisations and visits to the emergency room
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: NRS score of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macroelements levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and/or Maximum Administered Dose (MAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes